<DOC>
	<DOC>NCT02191579</DOC>
	<brief_summary>This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.</brief_summary>
	<brief_title>Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>History of chronic migraine More than 15 headache days in a 28 day period (headaches that last more than 4 hours and/or require treatment with prescription medication). Taking opioidcontaining products for acute headache treatment more than 8 days during a 28day period Previous treatment with botulinum toxin of any serotype for any reason Previous treatment with topiramate On a ketogenic diet (high in fat, low in carbohydrates) History of acute myopia or increased intraocular pressure Diagnosis of myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis or any other significant disease that might interfere with neuromuscular function Acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints for headache, or injection of anesthetics/steroids in the 4 weeks prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>